CDC: No quarantine required for those who have received the new crown vaccine and meet the conditions

The Centers for Disease Control and Prevention (CDC) said in updated guidance on its website Wednesday (Feb. 10) that certain people who have been vaccinated against the Chinese communist virus (COVID-19) may not need to be quarantined after exposure to an environment with the virus if they meet two conditions.

The CDC says, “Fully vaccinated individuals who meet the criteria will no longer need to be quarantined after exposure to a patient infected with the CCP virus.” It also provides additional considerations for patients and residents in healthcare facilities.

According to the CDC, a “fully vaccinated” person is an individual who has received two doses or a single full dose of vaccine for more than two weeks. To avoid quarantine, individuals also need to meet two additional criteria, namely that they remain “symptom-free from exposure to the CCA virus for three months after the last dose of vaccine.

The CDC added that people who do not meet these three criteria should follow its isolation guidance. The guidance also states that after exposure to a person infected with the CCP virus, they should distance themselves from others for a period of two weeks.

Those who are “fully vaccinated” and have been exposed to the CCP virus still need to be observed for two weeks for the development of symptoms. In addition, they still need to follow the CDC’s current guidelines to reduce the spread of the virus, which include wearing a mask, maintaining a social distance of six feet from others, avoiding crowds and staying out of poorly ventilated areas, and practicing good personal hygiene.

The CDC said, “This recommendation to waive isolation is derived from the claim that vaccination produces natural immunity.” It added, “Vaccination has been shown to prevent symptomatic Wuhan pneumonia, whereas for asymptomatic infected individuals, vaccination is considered less useful in preventing transmission of the virus.”

Currently, the U.S. Food and Drug Administration (FDA) has authorized two vaccines for emergency use in the United States. One is manufactured by Pfizer and its partner BioNTech, and the other is manufactured by Moderna and the National Institutes of health (NIH). The FDA will grant emergency use approval for Johnson & Johnson’s vaccine later this month.

Under U.S. law, drug manufacturers cannot be sued in court or be required to pay damages for injuries caused by vaccines or other countermeasures against the CCP virus.

The FDA’s approval of Pfizer’s vaccine marks the first Time it has approved a vaccine using ribonucleic acid “RNA” (mRNA) technology. This mRNA carries a portion of the genetic material from the stinger protein of this genetically Sars-New Coronavirus 2 (SARS-CoV-2) CCP virus and is used to trigger an immune system response that allows the body to detect and fight the intact virus.

The FDA issued a bulletin saying, “When a person is injected with this vaccine, their body produces a replica of the spike-in protein that does not cause disease but triggers the immune system to learn a defensive response that produces an immune response against Sars-CoV-2 (SARS-CoV-2).”

The Moderna vaccine uses the same mRNA technology. Moderna’s chief medical officer, Dr. Tal Zaks, said the two vaccines are not identical in composition, and that some of the lipids or fats that encase the vaccine are different. I wouldn’t assume” that all adverse reactions are the same, he said earlier in response to a question about the number of recipients who have had adverse physical reactions to the vaccine.